Share Price and Basic Stock Data
Last Updated: November 13, 2025, 8:12 pm
| PEG Ratio | -11.47 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Arvee Laboratories (India) Ltd operates in the specialty chemicals sector, focusing on diverse chemical solutions. The company reported a market capitalization of ₹181 Cr and a share price of ₹164. Over the past fiscal years, Arvee’s revenue trends displayed significant fluctuations. For instance, sales for the financial year ending March 2023 stood at ₹61.35 Cr, a notable increase from ₹40.33 Cr in FY 2022. However, the revenue sharply declined to ₹30.35 Cr in FY 2024 before recovering slightly to ₹38.49 Cr in FY 2025. Quarterly performance also reflects volatility, with the most recent quarterly sales in June 2025 reported at ₹7.48 Cr. This inconsistency in revenue generation indicates potential challenges in market demand or operational efficiency. The trailing twelve months (TTM) revenue stood at ₹35.37 Cr, which further emphasizes the need for strategic measures to stabilize and grow revenue streams in a competitive industry.
Profitability and Efficiency Metrics
Arvee Laboratories’ profitability metrics reveal a mixed performance landscape. The operating profit margin (OPM) for FY 2025 stood at 9.38%, reflecting a decline from 11.88% in FY 2023. The net profit margin also showed variability, with a recorded figure of 5.57% for FY 2025, compared to 6.71% in FY 2023. Net profit for FY 2025 was ₹2.15 Cr, a recovery from ₹1.05 Cr in FY 2024 but a decrease from ₹4.12 Cr in FY 2023. The company’s return on equity (ROE) stood at 7.12%, while return on capital employed (ROCE) was reported at 10.0%, suggesting moderate efficiency in utilizing equity and capital. The cash conversion cycle (CCC) is notably high at 102.25 days, indicating potential inefficiencies in inventory management and receivables collection. Overall, while there are positive indicators of profitability, the declining margins and high CCC pose challenges to operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Arvee Laboratories indicates a relatively strong financial position, with total assets recorded at ₹38.16 Cr and total liabilities at ₹38.19 Cr, suggesting a balanced capital structure. The company’s reserves increased to ₹20.24 Cr in FY 2025, up from ₹17.04 Cr in FY 2023, highlighting its ability to retain earnings for future growth. Borrowings remained low at ₹1.03 Cr, implying minimal reliance on debt, which is reflected in a long-term debt to equity ratio of just 0.03. The interest coverage ratio (ICR) stood at a robust 17.19 times, indicating strong capability to meet interest obligations. However, the price-to-book value (P/BV) ratio of 5.01x is relatively high compared to typical sector norms, suggesting that the stock may be overvalued in relation to its book value. Overall, while the balance sheet shows strength, the high valuation metrics warrant cautious consideration.
Shareholding Pattern and Investor Confidence
Arvee Laboratories maintains a stable shareholding pattern, with promoters holding 73.50% of the equity, reflecting strong control and commitment from the management. The public holds 26.50%, with the number of shareholders increasing to 1,505 as of June 2025, up from 864 in March 2023, indicating growing investor interest. This increase in shareholder base can be interpreted as a positive sign of confidence in the company’s future prospects. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could imply limited institutional support, which may affect stock liquidity and price stability. The consistent promoter stake combined with a rising public shareholder count suggests a potentially supportive environment for future capital raising or strategic initiatives, but the lack of institutional backing may pose risks in terms of price volatility.
Outlook, Risks, and Final Insight
The outlook for Arvee Laboratories appears cautiously optimistic, contingent on its ability to stabilize revenue and enhance profitability. The company’s strengths lie in its low debt levels, strong interest coverage, and growing reserves, which provide a cushion for future investments. However, risks include the volatility in sales and profit margins, as evidenced by recent financial performance. Additionally, high cash conversion cycles may hinder liquidity and operational efficiency. Moving forward, Arvee must focus on improving its operational metrics and addressing market demand fluctuations to leverage its strengths effectively. If the company can implement strategic initiatives that enhance revenue consistency and operational efficiency, it may unlock significant growth potential. Conversely, failure to address these challenges could lead to continued financial instability and diminished investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Arvee Laboratories (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 441 Cr. | 48.0 | 86.7/42.6 | 27.4 | 20.5 | 0.84 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 36.6 Cr. | 74.5 | 103/56.0 | 17.5 | 89.6 | 1.34 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 48.4 Cr. | 712 | 988/0.00 | 22.3 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,696 Cr. | 81.5 | 111/78.0 | 24.5 | 22.0 | 0.61 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 695 Cr. | 279 | 453/241 | 25.0 | 93.8 | 0.90 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,888.88 Cr | 735.29 | 49.95 | 182.90 | 0.41% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.18 | 22.74 | 16.25 | 12.56 | 7.60 | 8.91 | 7.70 | 6.14 | 10.60 | 12.53 | 8.91 | 6.45 | 7.48 |
| Expenses | 15.92 | 19.48 | 14.51 | 11.40 | 6.62 | 8.22 | 7.17 | 5.35 | 9.06 | 11.03 | 8.57 | 6.23 | 7.14 |
| Operating Profit | 2.26 | 3.26 | 1.74 | 1.16 | 0.98 | 0.69 | 0.53 | 0.79 | 1.54 | 1.50 | 0.34 | 0.22 | 0.34 |
| OPM % | 12.43% | 14.34% | 10.71% | 9.24% | 12.89% | 7.74% | 6.88% | 12.87% | 14.53% | 11.97% | 3.82% | 3.41% | 4.55% |
| Other Income | 0.02 | 0.06 | 0.07 | 0.06 | 0.09 | 0.09 | 0.19 | 0.21 | 0.11 | 0.16 | 0.19 | 0.21 | 0.17 |
| Interest | 0.11 | 0.11 | 0.09 | 0.07 | 0.07 | 0.08 | 0.05 | 0.05 | 0.08 | 0.05 | 0.05 | 0.07 | 0.04 |
| Depreciation | 0.64 | 0.48 | 0.49 | 0.48 | 0.35 | 0.42 | 0.35 | 0.37 | 0.31 | 0.30 | 0.28 | 0.27 | 0.29 |
| Profit before tax | 1.53 | 2.73 | 1.23 | 0.67 | 0.65 | 0.28 | 0.32 | 0.58 | 1.26 | 1.31 | 0.20 | 0.09 | 0.18 |
| Tax % | 24.84% | 25.27% | 25.20% | 100.00% | 24.62% | 25.00% | 25.00% | 81.03% | 25.40% | 25.19% | 25.00% | 22.22% | 5.56% |
| Net Profit | 1.14 | 2.05 | 0.92 | 0.01 | 0.49 | 0.21 | 0.24 | 0.12 | 0.94 | 0.98 | 0.15 | 0.07 | 0.17 |
| EPS in Rs | 1.03 | 1.86 | 0.83 | 0.01 | 0.44 | 0.19 | 0.22 | 0.11 | 0.85 | 0.89 | 0.14 | 0.06 | 0.15 |
Last Updated: August 20, 2025, 1:35 pm
Below is a detailed analysis of the quarterly data for Arvee Laboratories (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 7.48 Cr.. The value appears strong and on an upward trend. It has increased from 6.45 Cr. (Mar 2025) to 7.48 Cr., marking an increase of 1.03 Cr..
- For Expenses, as of Jun 2025, the value is 7.14 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.23 Cr. (Mar 2025) to 7.14 Cr., marking an increase of 0.91 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.34 Cr.. The value appears strong and on an upward trend. It has increased from 0.22 Cr. (Mar 2025) to 0.34 Cr., marking an increase of 0.12 Cr..
- For OPM %, as of Jun 2025, the value is 4.55%. The value appears strong and on an upward trend. It has increased from 3.41% (Mar 2025) to 4.55%, marking an increase of 1.14%.
- For Other Income, as of Jun 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Mar 2025) to 0.17 Cr., marking a decrease of 0.04 Cr..
- For Interest, as of Jun 2025, the value is 0.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.07 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.03 Cr..
- For Depreciation, as of Jun 2025, the value is 0.29 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.27 Cr. (Mar 2025) to 0.29 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.18 Cr.. The value appears strong and on an upward trend. It has increased from 0.09 Cr. (Mar 2025) to 0.18 Cr., marking an increase of 0.09 Cr..
- For Tax %, as of Jun 2025, the value is 5.56%. The value appears to be improving (decreasing) as expected. It has decreased from 22.22% (Mar 2025) to 5.56%, marking a decrease of 16.66%.
- For Net Profit, as of Jun 2025, the value is 0.17 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Mar 2025) to 0.17 Cr., marking an increase of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.15. The value appears strong and on an upward trend. It has increased from 0.06 (Mar 2025) to 0.15, marking an increase of 0.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 5:24 pm
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 26.82 | 34.44 | 47.78 | 54.90 | 45.42 | 47.38 | 40.33 | 61.35 | 30.35 | 38.49 | 35.37 |
| Expenses | 21.83 | 28.54 | 40.61 | 48.73 | 39.40 | 41.31 | 34.65 | 54.06 | 27.41 | 34.88 | 32.97 |
| Operating Profit | 4.99 | 5.90 | 7.17 | 6.17 | 6.02 | 6.07 | 5.68 | 7.29 | 2.94 | 3.61 | 2.40 |
| OPM % | 18.61% | 17.13% | 15.01% | 11.24% | 13.25% | 12.81% | 14.08% | 11.88% | 9.69% | 9.38% | 6.79% |
| Other Income | 0.10 | 0.51 | 0.23 | 0.35 | 0.35 | 0.56 | 0.46 | 1.35 | 0.64 | 0.66 | 0.73 |
| Interest | 3.07 | 3.48 | 3.33 | 1.63 | 0.99 | 0.58 | 0.37 | 0.39 | 0.25 | 0.25 | 0.21 |
| Depreciation | 1.49 | 2.07 | 2.15 | 2.35 | 2.29 | 2.41 | 2.32 | 2.08 | 1.50 | 1.15 | 1.14 |
| Profit before tax | 0.53 | 0.86 | 1.92 | 2.54 | 3.09 | 3.64 | 3.45 | 6.17 | 1.83 | 2.87 | 1.78 |
| Tax % | 66.04% | -81.40% | 43.23% | 11.02% | 25.89% | 26.37% | 25.51% | 33.23% | 42.62% | 25.09% | |
| Net Profit | 0.19 | 1.55 | 1.09 | 2.26 | 2.30 | 2.68 | 2.57 | 4.12 | 1.05 | 2.15 | 1.37 |
| EPS in Rs | 0.23 | 1.91 | 0.99 | 2.05 | 2.09 | 2.43 | 2.33 | 3.74 | 0.95 | 1.95 | 1.24 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 715.79% | -29.68% | 107.34% | 1.77% | 16.52% | -4.10% | 60.31% | -74.51% | 104.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | -745.47% | 137.02% | -105.57% | 14.75% | -20.63% | 64.42% | -134.83% | 179.28% |
Arvee Laboratories (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -5% |
| TTM: | -9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 22% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 9% |
| Last Year: | 7% |
Last Updated: September 4, 2025, 11:40 pm
Balance Sheet
Last Updated: May 13, 2025, 3:52 pm
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.05 | 4.05 | 5.51 | 5.51 | 5.51 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 |
| Reserves | -1.41 | 0.15 | 8.69 | 10.95 | 13.25 | 10.42 | 12.92 | 17.04 | 18.09 | 20.24 |
| Borrowings | 25.32 | 24.99 | 16.15 | 12.87 | 3.87 | 8.88 | 3.13 | 1.00 | 1.00 | 1.03 |
| Other Liabilities | 7.25 | 6.49 | 13.77 | 7.81 | 11.00 | 10.73 | 11.61 | 9.63 | 8.08 | 5.87 |
| Total Liabilities | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 38.16 |
| Fixed Assets | 13.15 | 16.88 | 14.88 | 12.65 | 13.18 | 13.81 | 13.84 | 12.68 | 12.67 | 15.27 |
| CWIP | 4.30 | 0.00 | 1.18 | 2.32 | 1.78 | 0.97 | 0.98 | 1.53 | 2.62 | 0.73 |
| Investments | 0.00 | 0.00 | 0.00 | 1.95 | 3.09 | 2.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 17.76 | 18.80 | 28.06 | 20.22 | 15.58 | 24.24 | 23.86 | 24.48 | 22.90 | 22.16 |
| Total Assets | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 38.16 |
Below is a detailed analysis of the balance sheet data for Arvee Laboratories (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 11.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 11.02 Cr..
- For Reserves, as of Mar 2025, the value is 20.24 Cr.. The value appears strong and on an upward trend. It has increased from 18.09 Cr. (Mar 2024) to 20.24 Cr., marking an increase of 2.15 Cr..
- For Borrowings, as of Mar 2025, the value is 1.03 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1.00 Cr. (Mar 2024) to 1.03 Cr., marking an increase of 0.03 Cr..
- For Other Liabilities, as of Mar 2025, the value is 5.87 Cr.. The value appears to be improving (decreasing). It has decreased from 8.08 Cr. (Mar 2024) to 5.87 Cr., marking a decrease of 2.21 Cr..
- For Total Liabilities, as of Mar 2025, the value is 38.16 Cr.. The value appears to be improving (decreasing). It has decreased from 38.19 Cr. (Mar 2024) to 38.16 Cr., marking a decrease of 0.03 Cr..
- For Fixed Assets, as of Mar 2025, the value is 15.27 Cr.. The value appears strong and on an upward trend. It has increased from 12.67 Cr. (Mar 2024) to 15.27 Cr., marking an increase of 2.60 Cr..
- For CWIP, as of Mar 2025, the value is 0.73 Cr.. The value appears to be declining and may need further review. It has decreased from 2.62 Cr. (Mar 2024) to 0.73 Cr., marking a decrease of 1.89 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 22.16 Cr.. The value appears to be declining and may need further review. It has decreased from 22.90 Cr. (Mar 2024) to 22.16 Cr., marking a decrease of 0.74 Cr..
- For Total Assets, as of Mar 2025, the value is 38.16 Cr.. The value appears to be declining and may need further review. It has decreased from 38.19 Cr. (Mar 2024) to 38.16 Cr., marking a decrease of 0.03 Cr..
Notably, the Reserves (20.24 Cr.) exceed the Borrowings (1.03 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -20.33 | -19.09 | -8.98 | -6.70 | 2.15 | -2.81 | 2.55 | 6.29 | 1.94 | 2.58 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82.61 | 87.12 | 118.25 | 52.66 | 52.40 | 60.70 | 109.78 | 72.94 | 73.48 | 79.66 |
| Inventory Days | 155.08 | 104.53 | 99.61 | 42.90 | 80.96 | 91.96 | 93.24 | 42.29 | 159.02 | 80.31 |
| Days Payable | 130.73 | 98.14 | 150.03 | 55.84 | 125.63 | 118.08 | 160.12 | 73.30 | 164.49 | 57.72 |
| Cash Conversion Cycle | 106.96 | 93.50 | 67.84 | 39.72 | 7.72 | 34.59 | 42.90 | 41.94 | 68.01 | 102.25 |
| Working Capital Days | 30.08 | 30.84 | 30.79 | -6.52 | 10.29 | -10.63 | 49.96 | 70.44 | 95.97 | 106.59 |
| ROCE % | 15.19% | 17.64% | 13.67% | 14.90% | 14.92% | 12.89% | 23.34% | 6.83% | 10.00% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| Diluted EPS (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| Cash EPS (Rs.) | 2.99 | 2.31 | 5.63 | 4.44 | 4.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 28.37 | 26.42 | 25.46 | 21.73 | 19.45 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 28.37 | 26.42 | 25.46 | 21.73 | 19.45 |
| Revenue From Operations / Share (Rs.) | 34.92 | 27.54 | 55.67 | 36.59 | 42.99 |
| PBDIT / Share (Rs.) | 3.87 | 3.25 | 7.83 | 5.56 | 6.01 |
| PBIT / Share (Rs.) | 2.83 | 1.89 | 5.95 | 3.46 | 3.83 |
| PBT / Share (Rs.) | 2.61 | 1.66 | 5.59 | 3.13 | 3.30 |
| Net Profit / Share (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| PBDIT Margin (%) | 11.08 | 11.78 | 14.07 | 15.19 | 13.98 |
| PBIT Margin (%) | 8.10 | 6.85 | 10.68 | 9.44 | 8.90 |
| PBT Margin (%) | 7.45 | 6.02 | 10.04 | 8.55 | 7.68 |
| Net Profit Margin (%) | 5.57 | 3.46 | 6.71 | 6.38 | 5.65 |
| Return on Networth / Equity (%) | 6.86 | 3.61 | 14.67 | 10.75 | 12.48 |
| Return on Capital Employeed (%) | 9.24 | 6.65 | 21.95 | 15.14 | 18.53 |
| Return On Assets (%) | 5.71 | 2.75 | 10.64 | 6.65 | 6.52 |
| Long Term Debt / Equity (X) | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 |
| Total Debt / Equity (X) | 0.03 | 0.03 | 0.03 | 0.13 | 0.41 |
| Asset Turnover Ratio (%) | 1.02 | 0.78 | 1.59 | 1.01 | 1.27 |
| Current Ratio (X) | 5.14 | 2.42 | 2.44 | 1.75 | 1.40 |
| Quick Ratio (X) | 3.95 | 1.50 | 1.92 | 1.33 | 0.99 |
| Inventory Turnover Ratio (X) | 7.03 | 3.08 | 7.48 | 3.53 | 4.18 |
| Interest Coverage Ratio (X) | 17.19 | 14.34 | 22.25 | 17.08 | 11.49 |
| Interest Coverage Ratio (Post Tax) (X) | 9.65 | 5.22 | 11.62 | 8.17 | 5.64 |
| Enterprise Value (Cr.) | 152.60 | 157.16 | 97.08 | 123.80 | 63.32 |
| EV / Net Operating Revenue (X) | 3.96 | 5.18 | 1.58 | 3.07 | 1.34 |
| EV / EBITDA (X) | 35.75 | 43.93 | 11.25 | 20.20 | 9.56 |
| MarketCap / Net Operating Revenue (X) | 4.07 | 5.21 | 1.58 | 3.11 | 1.29 |
| Price / BV (X) | 5.01 | 5.43 | 3.46 | 5.23 | 2.85 |
| Price / Net Operating Revenue (X) | 4.07 | 5.21 | 1.58 | 3.11 | 1.29 |
| EarningsYield | 0.01 | 0.01 | 0.04 | 0.02 | 0.04 |
After reviewing the key financial ratios for Arvee Laboratories (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 5. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 5. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 3. It has increased from 2.31 (Mar 24) to 2.99, marking an increase of 0.68.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.37. It has increased from 26.42 (Mar 24) to 28.37, marking an increase of 1.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.37. It has increased from 26.42 (Mar 24) to 28.37, marking an increase of 1.95.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 34.92. It has increased from 27.54 (Mar 24) to 34.92, marking an increase of 7.38.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.87. This value is within the healthy range. It has increased from 3.25 (Mar 24) to 3.87, marking an increase of 0.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.83. This value is within the healthy range. It has increased from 1.89 (Mar 24) to 2.83, marking an increase of 0.94.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.66 (Mar 24) to 2.61, marking an increase of 0.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 2. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For PBDIT Margin (%), as of Mar 25, the value is 11.08. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 11.08, marking a decrease of 0.70.
- For PBIT Margin (%), as of Mar 25, the value is 8.10. This value is below the healthy minimum of 10. It has increased from 6.85 (Mar 24) to 8.10, marking an increase of 1.25.
- For PBT Margin (%), as of Mar 25, the value is 7.45. This value is below the healthy minimum of 10. It has increased from 6.02 (Mar 24) to 7.45, marking an increase of 1.43.
- For Net Profit Margin (%), as of Mar 25, the value is 5.57. This value is within the healthy range. It has increased from 3.46 (Mar 24) to 5.57, marking an increase of 2.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.86. This value is below the healthy minimum of 15. It has increased from 3.61 (Mar 24) to 6.86, marking an increase of 3.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.24. This value is below the healthy minimum of 10. It has increased from 6.65 (Mar 24) to 9.24, marking an increase of 2.59.
- For Return On Assets (%), as of Mar 25, the value is 5.71. This value is within the healthy range. It has increased from 2.75 (Mar 24) to 5.71, marking an increase of 2.96.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.02. It has increased from 0.78 (Mar 24) to 1.02, marking an increase of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 5.14. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 5.14, marking an increase of 2.72.
- For Quick Ratio (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 2. It has increased from 1.50 (Mar 24) to 3.95, marking an increase of 2.45.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.03. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 7.03, marking an increase of 3.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.19. This value is within the healthy range. It has increased from 14.34 (Mar 24) to 17.19, marking an increase of 2.85.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.65. This value is within the healthy range. It has increased from 5.22 (Mar 24) to 9.65, marking an increase of 4.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 152.60. It has decreased from 157.16 (Mar 24) to 152.60, marking a decrease of 4.56.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.96. This value exceeds the healthy maximum of 3. It has decreased from 5.18 (Mar 24) to 3.96, marking a decrease of 1.22.
- For EV / EBITDA (X), as of Mar 25, the value is 35.75. This value exceeds the healthy maximum of 15. It has decreased from 43.93 (Mar 24) to 35.75, marking a decrease of 8.18.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has decreased from 5.21 (Mar 24) to 4.07, marking a decrease of 1.14.
- For Price / BV (X), as of Mar 25, the value is 5.01. This value exceeds the healthy maximum of 3. It has decreased from 5.43 (Mar 24) to 5.01, marking a decrease of 0.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has decreased from 5.21 (Mar 24) to 4.07, marking a decrease of 1.14.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Arvee Laboratories (India) Ltd:
- Net Profit Margin: 5.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.24% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.86% (Industry Average ROE: 24.61%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 9.65
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.95
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 136 (Industry average Stock P/E: 43.71)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.57%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | 403, Entice, Nr. Jayantilal Park BRTS, Ahmedabad Gujarat 380058 | compliance@arveelabs.com http://www.arveelabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shalin Sudhakarbhai Patel | Managing Director |
| Mr. Shalin Bharat Chokshi | Whole Time Director |
| Mrs. Neetu Rishi Jalan | Ind.& Non Exe.Director |
| Mr. Sachin Kanwarlal Kansal | Ind.& Non Exe.Director |
| Ms. Shalini Hitesh Jalan | Ind.& Non Exe.Director |
FAQ
What is the intrinsic value of Arvee Laboratories (India) Ltd?
Arvee Laboratories (India) Ltd's intrinsic value (as of 14 November 2025) is 224.40 which is 32.78% higher the current market price of 169.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 186 Cr. market cap, FY2025-2026 high/low of 233/127, reserves of ₹20.24 Cr, and liabilities of 38.16 Cr.
What is the Market Cap of Arvee Laboratories (India) Ltd?
The Market Cap of Arvee Laboratories (India) Ltd is 186 Cr..
What is the current Stock Price of Arvee Laboratories (India) Ltd as on 14 November 2025?
The current stock price of Arvee Laboratories (India) Ltd as on 14 November 2025 is 169.
What is the High / Low of Arvee Laboratories (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Arvee Laboratories (India) Ltd stocks is 233/127.
What is the Stock P/E of Arvee Laboratories (India) Ltd?
The Stock P/E of Arvee Laboratories (India) Ltd is 136.
What is the Book Value of Arvee Laboratories (India) Ltd?
The Book Value of Arvee Laboratories (India) Ltd is 28.4.
What is the Dividend Yield of Arvee Laboratories (India) Ltd?
The Dividend Yield of Arvee Laboratories (India) Ltd is 0.00 %.
What is the ROCE of Arvee Laboratories (India) Ltd?
The ROCE of Arvee Laboratories (India) Ltd is 10.0 %.
What is the ROE of Arvee Laboratories (India) Ltd?
The ROE of Arvee Laboratories (India) Ltd is 7.12 %.
What is the Face Value of Arvee Laboratories (India) Ltd?
The Face Value of Arvee Laboratories (India) Ltd is 10.0.